Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Ribonucleic Acid (RNA) Therapy Clinical Trials Market Through 2029?

The market size of clinical trials for ribonucleic acid (RNA) treatments has experienced significant growth in recent years. It is projected to rise from $2.57 billion in 2024 to $2.70 billion in 2025, showing a compound annual growth rate (CAGR) of 5.0%. The impressive growth during the historic period can be credited to the growing demand for new treatment methods, the successful development of mRNA vaccines, increasing funding for research, risen clinical trial activities, and a higher demand for comparative genomics.

The market size for clinical trials focusing on Ribonucleic Acid (RNA) therapy is projected to experience consistent expansion in the forthcoming years. It is forecasted to escalate to a value of $3.25 billion by 2029, at a Compound Annual Growth Rate (CAGR) of 4.8%. The anticipated growth during the forecast period can be credited to the escalating prevalence of unusual diseases, an increase in regulatory approvals, amplified investments in clinical research, a surge in patient involvement, and a rising emphasis on personalized medicine. Noteworthy trends expected to be observed within the forecast period include improved RNA delivery systems, breakthroughs in trial designs driven by biomarkers, the incorporation of artificial intelligence in trial design, the application of technology in decentralized clinical trials, and progression in fast-track pathways sanctioned by the regulatory authorities.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp

What Market Forces Are Driving The Ribonucleic Acid (RNA) Therapy Clinical Trials Sector In 2025 And Beyond?

The escalating prevalence of infectious diseases is predicted to fuel the expansion of the ribonucleic acid (RNA) therapy clinical trials market in the future. Infectious ailments, which are triggered by detrimental microorganisms, such as bacteria, viruses, fungi, or parasites, infiltrate the body, multiply and disrupt health. The surge in infectious diseases can be largely attributed to increased global travel, which expedites the swift dispersion of pathogens among different regions and populations. RNA therapy clinical trials play a significant role in fighting infectious diseases by fostering the development and assessment of pinpointed treatments capable of swiftly adjusting to novel pathogens. For example, in April 2025, a report released by the Minnesota Department of Health, a US-based state agency, revealed that the percentage of HIV cases among males aged 35 to 39 escalated from 10% in 2023 to 17% in 2024. Hence, the rising prevalence of infectious diseases is steering the growth of the RNA therapy clinical trials market.

How Is The Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Categorized By Segments?

The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –

1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)

2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV

3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas

Subsegments:

1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials

2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials

3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials

4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials

5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials

6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials

What Notable Trends Are Shaping The Direction Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?

In the RNA therapy clinical trials market, leading companies are focused on creating cutting-edge solutions including RNA-based antisense oligonucleotide therapy clinical trials. These trials target particular genetic sequences, regulate gene expression and provide highly targeted treatments for genetic and rare diseases. RNA-based antisense oligonucleotide therapy clinical trials are studies that explore the use of synthetic RNA strands to bind to specific messenger RNA targets. The goal is to control gene expression and cure genetic diseases. Sepul Bio, a biotechnology company based out of France, initiated the LUNA Phase 2b clinical trial in December 2024 to test ultevursen. This RNA-based antisense oligonucleotide therapy focuses on mutations in exon 13 of the USH2A gene, responsible for retinitis pigmentosa and Usher syndrome type 2a. The study, which covers 81 adults and children over eight from various global locations, is a two-year, double-masked, randomized, sham-controlled trial. The treatment aims to benefit individuals with retinitis pigmentosa or non-syndromic retinitis pigmentosa linked to exon 13 mutations in the USH2A gene, verified through genetic testing. The launch of the LUNA trial followed the promising results of earlier Phase 1/2 studies where ultevursen was observed to enhance visual acuity, retinal sensitivity, and retinal structure.

Which Firms Are Considered Leaders In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Space?

Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Charles River Laboratories International Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-therapy-clinical-trials-global-market-report

What Role Do Regional Policies And Investments Play In Ribonucleic Acid (RNA) Therapy Clinical Trials Market Expansion?

North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25896&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model